Guangzhou Innogen Pharmaceutl Grp Co Ltd
2591.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.64B
Close$
$3.84
2.1% upside
Current Fair Value
2.1% upsideUndervalued by 2.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.64 Billion |
|---|---|
| Enterprise Value | $948.63 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.76 |
| Beta | 1.41 |
| Outstanding Shares | 456,819,000 |
Return
| Return on Equity | -58.44% |
|---|---|
| Return on Assets | -42.35% |
| Return on Invested Capital | -57.88% |
Valuation & Multiples
| P/E Ratio | -4.14 |
|---|---|
| PEG | 81.01 |
| Price to Sales | - |
| Price to Book Ratio | 1.88 |
| Enterprise Value to Revenue | 4.6 |
| Enterprise Value to EBIT | -1.72 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Guangzhou Innogen Pharmaceutl Grp Co Ltd
193 employees
CEO: Qinghua Wang Guangzhou Innogen Pharmaceutical Group Co Ltd operates as a China-based investment holding firm with a core mission to research, develop, and bring to market medicinal products. The company specializes in producing innovative, human-comp...